Editas Medicine
EDIT
220 hedge funds and large institutions have $481M invested in Editas Medicine in 2023 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 76 increasing their positions, 62 reducing their positions, and 40 closing their positions.
75% more call options, than puts
Call options by funds: $6.11M | Put options by funds: $3.5M
23% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 62
2.27% less ownership
Funds ownership: 77.04% → 74.77% (-2.3%)
7% less capital invested
Capital invested by funds: $517M → $481M (-$35.8M)
7% less funds holding
Funds holding: 237 → 220 (-17)
38% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$31.3M |
| 2 |
BlackRock
New York
|
+$4.84M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$4.38M |
| 4 |
Squarepoint
New York
|
+$4.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$24.7M |
| 2 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$8.02M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.47M |
| 4 |
Man Group
London,
United Kingdom
|
-$6.35M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$5.52M |
EDIT Hedge Fund Activity: Q3 2023 in Review
220 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2023, worth a combined $481M — down 6.9% from $517M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of EDIT and 25 opened new positions — a net loss of 15 holders — while 62 trimmed existing stakes and 76 added.
The largest buyer was Deep Track Capital, adding an estimated $31.3M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $24.7M sold.
- 220 institutional investors held Editas Medicine (EDIT) as of Q3 2023, down from 237 in Q2 2023.
- Funds reported $481M of Editas Medicine stock for Q3 2023, down 6.9% quarter-over-quarter.
- 25 funds opened new Editas Medicine positions in Q3 2023 and 40 closed out, a net change of -15 holders.
- The largest Editas Medicine buyer in Q3 2023 was Deep Track Capital, an estimated $31.3M added.
- The largest Editas Medicine seller in Q3 2023 was Avidity Partners Management, an estimated $24.7M sold.
Based on aggregated 13F filings for Q3 2023.